Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ChulaCov19 BNA159 and BNA159.2 Booster Study
NCT05605470Phase 2Completed
- Sponsor
- Technovalia
- Start
- Jan 2023
- Primary completion
- Jul 2024
- Modality
- Vaccine mRNA, mRNA Vaccines
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of ChulaCov19 in coronavirus disease 2019 (COVID-19) (3 arms), sponsored by Technovalia. Primary endpoints: Numbers and percentage of participants with immediate adverse events, Numbers and percentage of participants with solicited local or systemic reactions and 5 more. Started Jan 2023; status: completed.
02
Drugs
ChulaCov19
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT05605470.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05605470.